Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162554 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL343309 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL30135703 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29434606 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL200589 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29588649 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8995746 | 0.99 | MAPT (0.52) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6112940 | 0.99 | MAPT (0.52) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Metyrosine SCHEMBL2722717 | 0.90 | BLM (0.62) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10077124 | 0.88 | MEN1 (0.52) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20250186634-A1 | METHODS OF TREATING SMALL CELL LUNG CANCER | Evergreen Discovery, LLC (US) | 2025-06-12 | — | — | US | claimed |
| US-20250154198-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2025-05-15 | — | — | US | claimed |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-30 | — | — | US | claimed |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-09 | — | — | US | claimed |
| WO-2024259115-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | claimed |
| WO-2024259147-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | claimed |
| WO-2024259132-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | claimed |
| EP-4440592-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-10-09 | — | — | EP | claimed |
| WO-2024206577-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-10-03 | — | — | WO | claimed |
| CN-118354781-A | Peptide inhibitors of interleukin-23 receptor | 西兰制药公司 | 2024-07-16 | — | — | CN | claimed |
| WO-2023099669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2023-06-08 | — | — | WO | claimed |
| EP-4076541-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-114845742-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2022-08-02 | — | — | CN | claimed |
| US-20220187315-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING DEPRESSION | DUKE UNIVERSITY | 2022-06-16 | — | — | US | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | disclosed |
| WO-2022026629-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | MAPT 3952/4885MEN1 528/4885KMT2A 2586/4885 |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | MAPT 3529/4885MEN1 488/4885KMT2A 2429/4885 |
| US-20250186634-A1 | METHODS OF TREATING SMALL CELL LUNG CANCER | SSTR2, CCKBR, GRPR | MAPT 4719/4885MEN1 54/4885KMT2A 1795/4885 |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDCD1LG2 | MAPT 3529/4885MEN1 488/4885KMT2A 2429/4885 |
| US-20250154198-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL33 | MAPT 1014/4885MEN1 3856/4885KMT2A 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.